Direct oral anticoagulants in the treatment of pulmonary embolism

References

• Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010;38:S495-S501
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-46
   PubMed Web of Science ®Google Scholar
• Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121:877-905
   PubMed Web of Science ®Google Scholar
• Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992;326:1240-5
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315-52
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-69a-k
   PubMed Web of Science ®Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30:829-37
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-11
   PubMed Web of Science ®Google Scholar
• Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992;20:520-6
   PubMed Web of Science ®Google Scholar
• Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041-6
   PubMed Web of Science ®Google Scholar
• Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010;170:1383-9
   PubMed Web of Science ®Google Scholar
• Meyer G, Vicaut E, Konstantinides SV. Fibrinolysis for intermediate-risk pulmonary embolism. N Engl J Med 2014;371:581-2
   PubMedGoogle Scholar
• Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41-8
   PubMed Web of Science ®Google Scholar
• Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9:1500-7
   PubMed Web of Science ®Google Scholar
• Zondag W, Vingerhoets LM, Durian MF, et al. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost 2013;11:686-92
   PubMed Web of Science ®Google Scholar
• Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013;2013:464-70
   PubMed Web of Science ®Google Scholar
• Pradaxa (dabigatran etexilate mesylate) capsules for oral use. Full prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2015
   Google Scholar
• Xarelto (rivaroxaban) tablets for oral use. Full prescribing information. Titusville (NJ): Janssen Pharmaceutical Inc., 2016
   Google Scholar
• Eliquis (apixaban) tablets for oral use. Full prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2016
   Google Scholar
• Savaysa (edoxaban) tablets for oral use. Full prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2016
   Google Scholar
• Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104:49-60
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Schellong S, Kakkar A, et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost 2016;116:714-21
   PubMed Web of Science ®Google Scholar
• Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Prandoni P, Prins MH, Cohen AT, et al. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboembolism in the EINSTEIN DVT and EINSTEIN PE studies. Acad Emerg Med 2015;22:142-9
   PubMed Web of Science ®Google Scholar
• Prins MH, Bamber L, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015;135:281-8
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
   PubMed Web of Science ®Google Scholar
• Liu X, Johnson M, Mardekian J, et al. Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc 2015;4:e002340
   PubMed Web of Science ®Google Scholar
• Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 2015;10:e0144856
   PubMed Web of Science ®Google Scholar
• Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
   PubMed Web of Science ®Google Scholar
• Brekelmans MP, Ageno W, Beenen LF, et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016;3:e437-45
   PubMed Web of Science ®Google Scholar
• Preblick R, Kwong WJ, White RH, et al. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. Hosp Pract 2015;43:249-57
   PubMedGoogle Scholar
• Dentali F, Di Minno MN, Gianni M, et al. Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Intern Emerg Med 2015;10:507-14
   PubMed Web of Science ®Google Scholar
• Mumoli N, Cei M, Pesavento R, et al. Are direct oral anticoagulants equally effective in reducing deep vein thrombosis and pulmonary embolism? Int J Cardiol 2015;187:645-7
   PubMed Web of Science ®Google Scholar
• Ageno W, Mantovani LG, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016;3:e12-21
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gitt AK, Bauersachs R, et al. The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry. Thromb J 2015;13:41
   PubMed Web of Science ®Google Scholar
• Singer AJ, Xiang J, Kabrhel C, et al. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): rationale and design. Acad Emerg Med 2016;23:1280-6
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Falanga A, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2015;11:e442-4
   PubMed Web of Science ®Google Scholar
• Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Canc Netw 2015;13:1079-95
   PubMed Web of Science ®Google Scholar
• Delate T, Witt DM, Ritzwoller D, et al. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist 2012;17:419-27
   PubMed Web of Science ®Google Scholar
• Wittkowsky AK. Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 2006;4:2090-1
   PubMed Web of Science ®Google Scholar
• Posch F, Konigsbrugge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015;136:582-9
   PubMed Web of Science ®Google Scholar
• Mazilu L, Parepa IR, Suceveanu AI, et al. Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovasc Res 2014;103:S39
   Web of Science ®Google Scholar
• Raskob GE, van Es N, Segers A, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 2016;3:e379-87
   PubMed Web of Science ®Google Scholar
• Bach M, Bauersachs R. Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE. Thromb Haemost 2016;116:S24-S32
   PubMed Web of Science ®Google Scholar
• van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015;114:1268-76
   PubMed Web of Science ®Google Scholar
• Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21
   PubMedGoogle Scholar
• Rouaud A, Hanon O, Boureau AS, et al. Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study. PLoS One 2015;10:e0119043
   PubMed Web of Science ®Google Scholar
• Rankin J, Nagar M, Crosby J, et al. Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep 2016;10:346
   PubMedGoogle Scholar
• Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-20
   PubMed Web of Science ®Google Scholar
• Praxbind (idarucizumab) injection for intravenous use. Full prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2015
   Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9
   PubMed Web of Science ®Google Scholar
• Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015;131:82-90
   PubMed Web of Science ®Google Scholar
• Goodacre S, Sampson F, Thomas S, et al. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Med Imaging 2005;5:6
   PubMedGoogle Scholar
• Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131-41
   PubMed Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017;117:238-45
   PubMed Web of Science ®Google Scholar
• Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016;172:315-36
   PubMed Web of Science ®Google Scholar
• Samama MM, Amiral J, Guinet C, et al. Monitoring plasma levels of factor Xa inhibitors: how, why and when? Expert Rev Hematol 2013;6:155-64
   PubMed Web of Science ®Google Scholar
• Weitz JI, Eikelboom JW. Urgent need to measure effects of direct oral anticoagulants. Circulation 2016;134:186-8
   PubMed Web of Science ®Google Scholar
• Amin A. Choosing non-vitamin K antagonist oral anticoagulants: practical considerations we need to know. Ochsner J 2016;16:531-41
   PubMed Web of Science ®Google Scholar